Comparing GLP-1 Drugs for Risk of Severe Diabetic Eye Disease
Among GLP-1 receptor agonists, semaglutide, dulaglutide, liraglutide, and exenatide show similar risks of sight-threatening diabetic retinopathy in routine clinical practice.
Quick Facts
What This Study Found
Semaglutide, dulaglutide, liraglutide, and exenatide showed comparable risks of sight-threatening diabetic retinopathy complications in a large target trial emulation study.
Key Numbers
How They Did This
Retrospective observational study using target trial emulation framework with US commercial, Medicare Advantage, and Medicare fee-for-service claims data (2014-2022).
Why This Research Matters
Early semaglutide trial data raised concerns about diabetic eye disease risk. This real-world comparison across GLP-1 agents helps reassure clinicians and patients.
The Bigger Picture
This addresses one of the key safety concerns about GLP-1 receptor agonists and supports their continued use in diabetes management without elevated eye disease risk relative to each other.
What This Study Doesn't Tell Us
Observational design using claims data — may miss unreported eye events. Target trial emulation reduces but does not eliminate confounding. No comparison to non-GLP-1 treatments.
Questions This Raises
- ?Do newer GLP-1 agents like high-dose semaglutide carry different eye risks than the doses studied here?
- ?Does the speed of blood sugar reduction with GLP-1 drugs affect retinopathy risk?
Trust & Context
- Key Stat:
- Comparable risk across 4 GLP-1 RAs No significant differences in sight-threatening retinopathy between semaglutide, dulaglutide, liraglutide, and exenatide
- Evidence Grade:
- Target trial emulation using large insurance databases — strong observational evidence, though residual confounding possible.
- Study Age:
- Published in 2026; covers prescribing data through 2022.
- Original Title:
- Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.
- Published In:
- Ophthalmology. Retina, 10(2), 142-151 (2026)
- Authors:
- Barkmeier, Andrew J, Deng, Yihong(3), Swarna, Kavya Sindhu, Herrin, Jeph, Polley, Eric C, Umpierrez, Guillermo E, Galindo, Rodolfo J, Ross, Joseph S, Mickelson, Mindy M, McCoy, Rozalina G
- Database ID:
- RPEP-14843
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs cause eye problems?
This study found comparable and generally low risks of severe diabetic eye disease across all four GLP-1 medications studied. The risk appears related to rapid blood sugar changes rather than the drugs themselves.
Which GLP-1 drug is safest for my eyes?
This study suggests all four common GLP-1 receptor agonists carry similar risks of sight-threatening diabetic retinopathy, so eye safety alone should not drive the choice between them.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14843APA
Barkmeier, Andrew J; Deng, Yihong; Swarna, Kavya Sindhu; Herrin, Jeph; Polley, Eric C; Umpierrez, Guillermo E; Galindo, Rodolfo J; Ross, Joseph S; Mickelson, Mindy M; McCoy, Rozalina G. (2026). Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.. Ophthalmology. Retina, 10(2), 142-151. https://doi.org/10.1016/j.oret.2025.07.019
MLA
Barkmeier, Andrew J, et al. "Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.." Ophthalmology. Retina, 2026. https://doi.org/10.1016/j.oret.2025.07.019
RethinkPeptides
RethinkPeptides Research Database. "Risk of Sight-Threatening Diabetic Retinopathy with Glucagon..." RPEP-14843. Retrieved from https://rethinkpeptides.com/research/barkmeier-2026-risk-of-sightthreatening-diabetic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.